ATXI
Companies
NASDAQ
Avenue Therapeutics Inc.
Health Care
$0.24
-$1.76 (-88.00%)
Price Chart
Overview
About ATXI
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Market Cap
$3.2M
Volume
5.4K
Avg. Volume
23.5K
P/E Ratio
-0.09140127
Dividend Yield
0.00%
Employees
7.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.88
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ATXI shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025